Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01141595 · ClinicalTrials.gov registry record · NA
Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders
A NA study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT01141595 is a NA study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 10 participants.
The verdict
NCT01141595, a NA study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to develop biomarkers for central nervous system BH4 concentration in children with autism so they can be easily screened to determine if they may benefit from BH4 supplementation. Kuvan is a synthetic form of BH4. BH4 is an enzyme cofactor that is essential for several critical metabolic functions.
Interventions
- DRUG sapropterin dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01141595
The ClinicalTrials.gov registry entry for NCT01141595 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sapropterin dihydrochloride is the first listed.
NCT01141595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01141595 about?
NCT01141595 is a clinical study titled "Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders". The purpose of this study is to develop biomarkers for central nervous system BH4 concentration in children with autism so they can be easily screened to determine if they may benefit from BH4 supplementation. Kuvan is a synthetic form of BH4. BH4 is an enzyme cofactor that is essential for several ...
What is the current status of trial NCT01141595?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2010-07. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01141595?
The interventions under investigation include: sapropterin dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT01141595?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.